CHMP officially recommends Bavarian Nordic's vaccine for monkeypox in Europe

Bavarian Nordic’s vaccine was already approved in the monkeypox indication in the US and Canada – Imvanex is now one step closer to gaining the same authorization in Europe.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
by marketwire, translated by daniel pedersen

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted Bavarian Nordic a positive opinion to extend smallpox vaccine Imvanex’s indication to include monkeypox, the firm reported Friday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading